Skip Navigation
Skip to contents

KMJ : Kosin Medical Journal

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
6 "Prognosis"
Filter
Filter
Article category
Keywords
Publication year
Authors
Review article
Mucinous carcinoma of the breast: distinctive histopathologic and genetic characteristics
Minjung Jung
Kosin Med J. 2022;37(3):176-186.   Published online August 25, 2022
DOI: https://doi.org/10.7180/kmj.22.022
  • 413 View
  • 15 Download
Abstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
Mucinous carcinoma is a rare histologic type of breast cancer that, when classified with favorable histology, can be treated with different therapeutic options. This study reviews the histologic findings of mucinous carcinoma that support or exclude favorable histology and emphasizes the necessity of an appropriate gross examination with radiologic findings for an accurate diagnosis. In addition, unusual findings such as micropapillary arrangements and lobular differentiation in mucinous carcinoma and their implications for prognosis and treatment are reviewed. Mucinous carcinoma involves upregulation of MUC2, a mucus-associated gene common in mucinous carcinoma of the breast as well as various other organs. In mucinous carcinoma, the fraction of genome altered and tumor mutation burden are lower than those of invasive carcinoma of no special type, the most common histology of breast cancer. In addition, the genetic alterations found in mucinous carcinoma are diverse, unlike the pathognomonic genetic alterations observed in other histologic types of breast cancer. These genetic features support the importance of conventional microscopic evaluations for the pathologic differential diagnosis of mucinous carcinoma of the breast in routine practice. A variety of breast lesions, including mucinous cystadenocarcinoma and mucocele-like lesions, as well as mucinous carcinoma from other organs, can mimic mucinous carcinoma of the breast. In order to obtain an accurate pathologic diagnosis, careful evaluation of the overall histopathologic characteristics and ancillary testing are required to provide information on appropriate treatment and prognosis.
Original articles
Prognostic Value of Procalcitonin in Pneumonia among Patients Admitted to Intensive Care Unit.
Deok Hee Kim, Hae Won Jung, Hyung Koo Kang
Kosin Med J. 2019;34(1):15-23.   Published online June 30, 2019
DOI: https://doi.org/10.7180/kmj.2019.34.1.15
  • 468 View
  • 3 Download
Abstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
Objectives

Pneumonia is one of the leading causes of death in the intensive care unit (ICU). Many biomarkers for predicted prognosis have been suggested; among these, procalcitonin (PCT) is known to increase in cases of bacterial infection. However, there have been many debates regarding whether PCT is an appropriate prognostic marker for pneumonia. Therefore, we investigated whether PCT can serve as a biomarker for pneumonia, and compared it with CURB-65, which is a known tool for predicting the prognosis of pneumonia.

Methods

Levels of PCT and CURB-65 scores were compared between 30-day non-survival (n = 30) and survival (n = 101) patients. Relationships between PCT and CURB-65 were determined by using linear regression analysis, as well as by using receiver operating characteristic (ROC) curve analysis and calculation of the area under the curve (AUC). High and low PCT groups were compared.

Results

High PCT and high CURB-65 score were positively associated with 30-day mortality. For the prediction of 30-day mortality, initial PCT and CURB-65 exhibited AUCs of 0.63 and 0.66; these were not significantly different (P = 0.132). We found that the high PCT group had a higher rate of initial treatment failure (91%, P = 0.004).

Conclusions

Initial PCT can be a prognostic biomarker for mortality in severe pneumonia, similar to the CURB-65 score. Initial high PCT was positively associated with initial treatment failure.

Outcome of Ductal Carcinoma in Situ in Patients with or Without p53 Mutations
Dong Won Ryu, Chung Han Lee
Kosin Med J. 2012;27(2):119-125.   Published online December 27, 2012
DOI: https://doi.org/10.7180/kmj.2012.27.2.119
  • 353 View
  • 1 Download
  • 1 Citations
Abstract PDFPubReader   ePub   CrossRef-TDMCrossref - TDM
Objectives

p53 is a tumor suppressor gene and plays an important role in the etiology of breast cancer. The aim of this study is to clarify clinical significance of p53 in Ductal Carcinoma in situ (DCIS), and discuss about survival effect.

Methods

The study subjects, 69 women with breast cancer, were a subset of patients operated from Jan 2005 to Dec 2006. We used a cutoff of 10% to distinguish between positive and negative p53 staining. The University of Southern California (USC)/Van Nuys Prognostic Index (VNPI) were compared with 2 categories of p53.

Results

The positivity of p53 was found in 20 patients (29.0%) in DCIS. And negativity of p53 was found in 49 patients (71.0%). And 15 patients (21.7%) had a low USC/VNPI score, 42 patients (60.9%) intermediate and 12 patients (17.4%) a high score. The positivity of p53 was correlated with high USC/VNPI (P = 0.001). The univariate analysis for prognostic factors associated with Disease Free Survival (DFS) revealed that patients with p53 positivity show shorter Disease Free Survival (DFS) than patients with p53 negativity (P = 0.013) and USC/VNPI was also statistically significant (P = 0.030).

Conclusions

According to our study, p53 was associated with high USC/VNPI. These findings suggest that p53 can be used to classify DCIS into at least two subtypes with differing prognoses.

Citations

Citations to this article as recorded by  
  • Effect of Docosahexaenoic Acid (DHA) on Breast Cancer Cells
    Sun-yong Hwang, Tae-Hee Kim, Hae-Hyeog Lee, Heung Yeol Kim, Juhyun Seo
    Kosin Medical Journal.2015; 30(2): 103.     CrossRef
Peripheral Blood Lymphokine-Activated Killer Cell Activity Can Predict Response to Conventional Chemotherapy in Aggressive Non-Hodgkin's Lymphomas
Wan Kyu Eo, Dae Hyun Kim, Seong Hoon Chang, Jee Young Lee, yang So Kim
Kosin Med J. 2000;15(1):29-38.
  • 101 View
  • 0 Download
PDF
Serum LDH as A Prognostic Factor in Aggressive Non-Hodgkin's Lymphoma
Wan Kyu Eo, Jee Hyun Lee, Jong Chul Kim
Kosin Med J. 2004;19(1):77-85.
  • 100 View
  • 0 Download
PDF
Prognostic Value of Serum B2-microglobulin in Diffuse Large B-cell Lymphomas
Wan Kyu Eo, Seong Hoon Shin
Kosin Med J. 2006;21(1):61-68.
  • 94 View
  • 1 Download
PDF

KMJ : Kosin Medical Journal